- Reaction score
- 2,721
Aclaris Therapeutics announced that the first patient has been dosed in their phase 2 open-label study of ATI-502 in male and female androgenic alopecia. ATI-502 is a topical JAK inhibitor for JAK1 and JAK3. The trial will include 12 male and 12 female subjects who will receive topical applications of ATI-502 twice daily.
Dr. Stuart Shanler, Chief Scientific Officer of Aclaris, had this to say about the trial: “This trial is the first step in evaluating the potential clinical benefit of ATI-502 topical solution in treating patients with Androgenetic Alopecia, or male/female pattern baldness,This is an important step forward in understanding the clinical utility of our JAK inhibitors in patients with Androgenetic Alopecia.”
From http://www.folliclethought.com/
Dr. Stuart Shanler, Chief Scientific Officer of Aclaris, had this to say about the trial: “This trial is the first step in evaluating the potential clinical benefit of ATI-502 topical solution in treating patients with Androgenetic Alopecia, or male/female pattern baldness,This is an important step forward in understanding the clinical utility of our JAK inhibitors in patients with Androgenetic Alopecia.”
From http://www.folliclethought.com/